Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina, Austria, Australia, Canada, Denmark, France, Germany, Italy, New Zealand, Poland, Portugal, Spain, Switzerland, UK and USA). It is starting on the United States, but additional locations in North America, Europe, South America and Oceania will be posted on clinical trial directories as soon as there is an approval.
See the full statement هنا.
The European Huntington Association is hosting a webinar about this study on the 19th January, at 6 p.m. CET. You can register هنا.